Another great aspect is the ultra-rare sarcoma. These sarcomas are molecularly characterized, so they were discovered only recently. And we launched this program globally. It’s called Graceful, where through molecular screening, patients that are similar to Ewing sarcoma, like a round cell sarcoma, they have characterized and we found out that their prognosis is much, much poorer, in particular, Ewing sarcoma, they have a very poor prognosis...
Another great aspect is the ultra-rare sarcoma. These sarcomas are molecularly characterized, so they were discovered only recently. And we launched this program globally. It’s called Graceful, where through molecular screening, patients that are similar to Ewing sarcoma, like a round cell sarcoma, they have characterized and we found out that their prognosis is much, much poorer, in particular, Ewing sarcoma, they have a very poor prognosis. So with this matching AI, when a drug will become available for a specific fusion or co-occurrence molecular alteration, also these patients will maybe have access to a cure and there is really a practice change for these patients which are unlikely to have the opportunity to participate in a trial specific for the disease because they are so rare that it is not even feasible. So the only way is a precision medicine approach.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
